Lupin, a second largest pharma company with net sales of Rs. 17,100 crore plus, has received final approval for its nadolol tablets USP, 20 mg, 40mg, and 80 mg from the US FDA to market a generic version of US WorldMeds, LLC's Corgard tablets.
Lupin scrip moved up smartly by Rs. 23.90 in the morning session on BSE to Rs. 1063.70. The scrip touched to its yearly highest level at Rs. 1572.25 on February 6, 2017. Current market capitalisation worked out to Rs. 48,024 crore.
Lupin's nadolal tablets are indicated for management of patients with angina pectoris and for the treatment of hypertension. These tablets had annual sales of approximately US$ 110 million in the US.
Lupin gets, us fda approval, generic corgard tablets
